Andy Pasternak - 27 Dec 2022 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP, Chief Strategy Officer
Signature
/s/ Patrick McIlvenny, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
27 Dec 2022
Net transactions value
$0
Form type
4
Filing time
29 Dec 2022, 15:28:38 UTC
Previous filing
14 Dec 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Performance Restricted Stock Units (PSUs) Award $0 +26,124 $0.000000 26,124 27 Dec 2022 Ordinary Shares 26,124 Direct F1, F2
transaction HZNP Performance Restricted Stock Units (PSUs) Award $0 +17,464 $0.000000 17,464 27 Dec 2022 Ordinary Shares 17,464 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each PSU represents a contingent right to receive one ordinary share of the Issuer.
F2 On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met. The ordinary shares subject to the PSUs vest on December 30, 2022.
F3 On January 4, 2021, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On December 27, 2022, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on December 30, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2024.